SARS-CoV-2/COVID-19: Evidence-Based Recommendations on Diagnosis and Therapy
| Autor: | Petra Wegermann, Susanne Huggett, Martin F. Bachmann, Berthold Bein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
ARDS Evidence-based practice medicine.medical_treatment Fulminant Lung injury 03 medical and health sciences 0302 clinical medicine Intensive care Maternity and Midwifery Obstetrics and Gynaecology medicine Extracorporeal membrane oxygenation Review/Übersicht personal protection equipment GebFra Science Intensive care medicine Intensivtherapie Personal protective equipment FFP3 persönliche Schutzausrüstung 030219 obstetrics & reproductive medicine Lung business.industry SARS-CoV-2 Obstetrics and Gynecology COVID-19 adult respiratory distress syndrome medicine.disease critical care medicine.anatomical_structure acute lung injury N95 respiratory masks akutes Lungenversagen business |
| Zdroj: | Geburtshilfe und Frauenheilkunde |
| ISSN: | 1438-8804 0016-5751 |
| Popis: | COVID-19, a new viral disease affecting primarily the respiratory system and the lung, has caused a pandemic posing serious challenges to healthcare systems around the world. In about 20% of patients, severe symptoms occur after a mean incubation period of 5 – 6 days; 5% of patients need intensive care therapy. Mortality is about 1 – 2%. Protecting healthcare workers is of paramount importance in order to prevent hospital-acquired infections. Therefore, during all procedures associated with aerosol production, personal protective equipment consisting of a FFP2/FFP3 (N95) respiratory mask, gloves, safety glasses and a waterproof overall should be used. Therapy is based on established recommendations issued for patients with acute lung injury (ARDS). Lung protective ventilation, prone position, restrictive fluid management and adequate management of organ failure are the mainstays of therapy. In case of fulminant lung failure, veno-venous extracorporeal membrane oxygenation may be used as a rescue in experienced centres. New, experimental therapies are evolving with ever increasing frequency; currently, however, no evidence-based recommendation is possible. If off-label and compassionate use of these drugs is considered, an individual benefit-risk assessment is necessary, since serious side effects have been reported. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|